Insight Into the Perioperative Management of Type 2 Diabetes

Syed Owais Zaidi 1, 2, Yusra Khan 3, Bibli S. Razak 1, Bilal Haider Malik 1

1. Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA 2. Internal Medicine, Mukhtar Sheikh Hospital, Multan, PAK 3. Pharmacy, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA

Corresponding author: Syed Owais Zaidi, owaiszaidi87@hotmail.com

Abstract

Diabetic people are at risk of developing acute complications when exposed to stress. Surgery brings a stressful period when the patient is exposed not only to surgical stress but also the effects of medications used during that particular period. The patient’s comorbidities can influence the perioperative management of diabetes. Poorly controlled diabetes can complicate the hospital course.

The literature was searched through PubMed and the articles of the last 5 years, from 2014 to 2019, were looked into. The studies available as a free text, in the English language and related to humans, were included. Inclusion criteria also included adults with type 2 diabetes undergoing surgery.

The perioperative management of diabetes is a challenging one. Apart from the diabetes control; comorbidities, general health, intake, and interaction of medications both anti-diabetic and non-diabetic, type and duration of surgery, are some of the factors that influence the outcome of the surgery. With a variety of options available to manage diabetes currently, it is important to have a good insight into their effects to prevent complications to occur and ensure safe discharge from the hospital. The good control of diabetes is essential in bringing favorable outcomes.

The perioperative management of diabetes should be individualized. Oral anti-hyperglycemic medications, other than sulfonylureas and SGLT2 inhibitors, provide a reasonable alternative to insulin and can be continued safely perioperatively depending upon the type of surgery and the patient is expected to resume oral intake soon postoperatively.

Categories: Anesthesiology, Endocrinology/Diabetes/Metabolism, Internal Medicine

Keywords: perioperative management, diabetes, hyperglycemia, high blood sugars

Introduction And Background

The diabetic population is prone to have a complicated hospital course along with the risk of perioperative complications [1]. According to the figure quoted by International Diabetes Federation in 2017, 425 million people between the age range of 18-99, are affected with diabetes and this number is expected to touch 693 million in 2045 [2]. It is essential to review the treatment of diabetes and its complications before undertaking surgery with regard to its effects on fluid and electrolyte balance and cardiovascular system, in terms of interactions with other drugs and the other illnesses like kidney disease, autonomic disorders, coronary artery disease, vascular disease, and high blood pressure [1].

Screening for diabetes is recommended in every patient being planned for surgery [1]. A review of a recent hemoglobin A1c (HbA1c) level before surgery permits risk assessment and attempt to achieve good glycemic control (HbA1c < 69 mmol/l) [3-4]. Hemoglobin A1c (HbA1c) provides an average estimate of blood sugars over the last three months in diabetic patients, thereby not only representing the quality of diabetic control but also permits review and adjustment in treatment to achieve the target, in addition to that, its raised value in some studies indicates a likelihood of early postoperative infection and myocardial infarction [5-6].

How to cite this article

Zaidi S, Khan Y, Razak B S, et al. (February 04, 2020) Insight Into the Perioperative Management of Type 2 Diabetes. Cureus 12(2): e6878. DOI 10.7759/cureus.6878
It has been found in the meta-analysis of studies involving patients with diabetes undergoing surgical procedures only that the blood sugar control in the range of 150-200 mg/dl (8.3-11.1 mmol/l) is associated with decreased perioperative mortality and stroke than a more relaxed target of > 200 mg/dl (11.1 mmol/l). Moreover, strict control between 100 and 150 mg/dl (5.6-8.3 mmol/l) does not result in an added advantage [7]. Surgery in diabetics places them at high risk to develop postoperative infections due to the adverse effects of diabetes on their immune status, wound healing, and blood supply through small vessels [8-10].

Perioperative treatment to achieve good control of diabetes with insulin, either in the form of infusion or bolus has been used over the years due to its rapid action and easy adjustment, however, due to the variability in insulin resistance among the patients, the response is unpredictable and optimal regimen is yet to be known [4, 11-15]. The advent of new treatments in diabetes opens the door of discussion regarding achieving control of diabetes, timing to withhold medications, an adjustment in doses or modification in the treatment, and interactions of the drugs perioperatively. The literature is reviewed to find the answer to these questions.

The search of the literature review is done using the internet and PubMed using the following six regular keywords and three MeSH Words:

**Regular keywords**
1. Perioperative: It brings the results of 116379.
2. Diabetes: It shows 709582 results.
3. Management: It comes up with the 2830280 results.
4. Complications: It reveals 3190876 results.
5. Insulin: It produces 400938 results.
6. Antidiabetics: It presents with 260645

Regular keywords are summarized in Table 1.

| KEYWORDS     | DATABASE   | NUMBER OF RESULTS |
|--------------|------------|-------------------|
| Perioperative| PubMed     | 116379            |
| Diabetes     | PubMed     | 709582            |
| Management   | PubMed     | 2830280           |
| Complications| PubMed     | 3190876           |
| Insulin      | PubMed     | 400938            |
| Antidiabetics| PubMed     | 260645            |

TABLE 1: Regular keywords

**MeSH strategy**

The below-mentioned picture emerges by employing MeSH strategy.

1. Perioperative is searched through MeSH and produces six results.
2. Diabetes in MeSH reveals 100 results.

3. Management via MeSH produces 53 results.

MeSH strategy is described in Table 2.

| MeSH WORDS | NUMBER OF RESULTS |
|------------|-------------------|
| Perioperative | 6 |
| Diabetes | 100 |
| Management | 53 |

**TABLE 2: MeSH strategy**

**Inclusion criteria**

The following inclusion criteria were used while searching the literature:

1. The last five years of articles were searched from 2014 to 2019.

2. Only free text available was made part of the search.

3. The studies related to humans only were taken into consideration.

4. Adults with type 2 diabetes were included in the review.

5. The review articles and randomized control trials (RCTs) were made part of the review.

6. All the articles were peer reviewed.

**Ethical issue**

All the data were collected ethically and legally.

**Quality assessment tool**

No quality assessment tool was applied.

**Review**

**Perioperative management of diabetes**

The common exercise is to hold all oral anti-diabetic medications on the day of undertaking surgery; however, this strategy does not deem fit for those patients undergoing surgery for a shorter period or are expected to resume their diet quickly or be discharged after having a short stay [16-17].

Those patients in whom the diet is withheld for a shorter period, the Association of Anesthetists of Great Britain and Ireland (AAGBI) guideline recommends an individualized approach with the option of carrying on with the antihyperglycemic medications that do not cause low blood sugars and metformin is no exception [18].

A joint Anesthesiology and Diabetology position statement from France also reinforces the idea of sticking with the non-insulin medications in daycare surgeries and only to be stopped in major procedures [19].
Given that, the existence of no definitive strategy to manage blood sugars perioperatively and diverse recommendations from different clinical bodies, it is not unexpected to observe in the audits like National Confidential Enquiry into Patient Outcome and Death (NCEPOD) study, the different approaches being employed in clinical settings to achieve blood glucose targets [20].

**Anti-hyperglycemic medications**

*Metformin*

It is the recommended first-line drug to be used in treating type 2 diabetes unless contraindicated [1]. In the past, it is stopped for about 48 hours before surgery because of the overestimated fear of lactic acidosis [21-22]. However, it is prudent to assess the following risk factors before deciding it to continue preoperatively or restart postoperatively [5]:

i. Renal impairment

ii. Use of contrast agents

iii. Dehydration

iv. Severe heart failure (EF < 30%)

Recently, the US Food and Drug Authority (FDA) has permitted it to continue unless the estimated glomerular filtration rate (eGFR) falls below 30 ml/min/1.73m² [1].

The American Diabetes Association (ADA) proposes holding of metformin on the day of surgery whereas the Association of Anesthetists of Great Britain and Ireland (AAGBI) suggests to continue it with the rest of the oral anti-diabetic medications other than sulfonylureas and sodium-glucose transport inhibitors (SGLT2) on the day of procedure as it does not cause low blood sugars [16, 23]. It might be safe to restart 48 hours after the major procedure and making sure of the adequate functioning of the kidney [5].

*Sulfonylureas*

Sulfonylureas have been in the horizon of treatment of diabetes for about 70 years and a usual strategy to withhold it on the day of surgery remains plausible as it is associated with a higher risk of asymptomatic hypoglycemia compare to other antihyperglycemic medications demonstrated in a Continuous Glucose Monitoring (CGM) study [1, 24].

A review of meta-analysis showed that high risk is attached with the use of sulfonylureas in causing hospitalization, congestive cardiac failure, and mortality [25].

*Sodium-Glucose Co-Transporters 2 (SGLT2) Inhibitors*

It is a relatively new class of drugs added to the armamentarium of diabetes management that is associated with good blood glucose control, decreased plasma volume, renal protection, and weight loss [26-28]. It works by facilitating the passage of blood glucose and sodium in the urine irrespective of insulin [29]. However, it is linked with genitourinary infections and diabetic ketoacidosis (DKA) especially euglycemic DKA [1, 30-31]. The occurrence of euglycemic DKA is likely to increase in the peri - and post-operative period if they are not stopped perioperatively or restarted very soon postoperatively [32-35]. The awareness of a risk of developing euglycemic is very important to those who undergo surgery and a very high index of suspicion should be present not to miss it [1]. SGLT2 inhibitors should be restarted postoperatively when the patient looks clinically well and resumes and tolerates his oral intake properly [1].

At present, there is no agreement on the withholding of SGLT2 inhibitors before surgery but the general strategy is to stop them before 24-72 hours or even longer [1, 34-35].

*Dipeptidyl Peptidase 4 (DPP 4) Inhibitors*
Their use is associated with low risk of hypoglycemia and to stick or discontinue with it perioperatively is unlikely to produce any significant complications and either strategy is acceptable [1].

**Glucagon-Like Peptide 1 (GLP-1) Agonists**

They are administered through injections and are not linked to produce hypoglycemia instead of nausea and vomiting can occur. Their long-term use is associated with cardiovascular benefit [1, 16, 36-41].

The glucose control is better achieved through GLP-1 agonist in comparison to insulin as shown in two randomized control studies of cardiac and non-cardiac patients undergoing surgery [16, 42]. However, gastrointestinal adverse effects may become limiting factors to their use [1]. Therefore, either plan of going with or against it perioperatively is workable [1].

**Insulin**

Perioperative insulin-based management in the form of basal-bolus is quite effective in attaining blood glucose targets than intermittent bolus with rapid-acting insulin in type 2 diabetes [43]. Insulin infusion is also an option and can be used in critical and non-critical situations [1].

Degludec has a long half-life of more than 42 hours and current data are not enough to determine its effect on perioperative blood sugars [1, 5].

The summary of antidiabetic medications used perioperatively is outlined in Table 3.

| Summary of Perioperative Use of Anti-Diabetic Medications |
|----------------------------------------------------------|
| **Metformin**                                            |
| The American Diabetes Association (ADA) proposes holding of metformin on the day of surgery whereas the Association of Anesthetists of Great Britain and Ireland (AAGBI) suggests to continue it with the rest of the oral anti-diabetic medications other than sulfonylureas and sodium-glucose transport inhibitors on the day of the procedure as it does not cause low blood sugars. It might be safe to restart 48 hours after the major procedure and making sure of the adequate functioning of the kidney |
| **Sulfonylurea**                                         |
| The usual strategy to withhold it on the day of surgery remains plausible |
| **Dipeptidyl peptidase 4 (DPP-4) inhibitors**             |
| To continue or discontinue it perioperatively is unlikely to produce any significant complications and either strategy is acceptable |
| **Sodium-glucose co-transporters 2 (SGLT2) inhibitors**   |
| At present, there is no agreement on the withholding of SGLT2 inhibitors before surgery but the general strategy is to stop them before 24–72 hours or even longer |
| **Glucagon-like peptide 1 (GLP1) agonists**              |
| Gastrointestinal adverse effects may become limiting factors to their use. Therefore, either plan of going with or against it perioperatively is workable |
| **Insulin**                                              |
| Perioperative insulin – based management in the form of basal-bolus is quite effective in attaining blood glucose target than intermittent bolus with rapid-acting insulin in type 2 diabetes. Insulin infusion is also an option and can be used in critical and non-critical situations. Degludec has a long half-life of more than 42 hours and current data are not enough to determine its effect on perioperative blood sugars |

**TABLE 3:** Summary of perioperative use of anti-diabetic medications

**Assessment of control of blood glucose levels**

Perioperative assessment of diabetic control is paramount and is evaluated by the following two methods.
There are several factors causing variation in blood sugar levels, some of them are [5]:

i. Fasting

ii. Stress

iii. Infection

iv. Medications such as steroids

Hemoglobin A1c (HbA1c) Levels

Hemoglobin A1c (HbA1c) level gives a good idea of the blood sugar level over the past three months, thereby helping in the modification of the treatment to obtain the target level [5-6]. Elevated HbA1c links to morbidity, mortality, cardiac injury, and postoperative infection [11]. It might be prudent to postpone the elective procedure when HbA1c level is found > 9% or < 5% to prevent the acute metabolic problems or occurrences of hypoglycemic episodes respectively, perioperatively [5].

Blood Glucose Levels

Blood sugars > 200 mg/dl are associated with morbidity and mortality in a postoperative period [44-46]. The demonstration of a recent dysregulation in blood glucose during perioperative monitoring is not reflected through HbA1c [5].

Hypoglycemia during the perioperative period can cause a significant challenge. In cases of autonomic dysfunction, it is not easy to pick and a close vigilance is required to manage it timely [45]. There are many factors that can predispose to low blood sugars including fasting state, irregular food intake postoperatively, impairment of renal or liver function, interactions with medications like quinolone, beta-blockers, heparin, trimethoprim-sulfamethoxazole, etc [5].

Perioperative risk assessment of type 2 diabetes

Perioperatively, the severity of the following complications of diabetes needs to be assessed:

1. Gastroparesis

2. Heart disease

3. Kidney disease

1. Gastroparesis

It is a quite common complication of long-standing diabetes and may be defined as the slow or delayed emptying of the stomach in the absence of mechanical obstruction [5]. It may present with the following symptoms [47]:

i. Anorexia

ii. Abdominal pain

iii. Nausea
iv. Vomiting

v. Early satiety

vi. Abdominal bloating

It can cause a disturbance in postprandial blood sugars [5]. It poses a risk of aspiration of food contents during anesthesia, therefore, it is important to specifically look for and manage this complication and avoid those medications that can further exacerbate this condition [5].

2. Cardiac Disease

Proper risk stratification of the cardiac disease including coronary artery disease, heart failure, and cardiac autonomic neuropathy should be undertaken through a detailed history, examination, and review of the recent cardiac investigations. High-risk cases should be further evaluated and consulted by the cardiologist.

3. Kidney Disease

Renal evaluation is required to avoid kidney injury postoperatively. Urine albumin to creatinine ratio (ACR) and the estimation of the glomerular filtration rate (eGFR) should be determined before performing major surgery [5]. Nephrotoxic agents should be avoided in high-risk cases.

Perioperative hyperglycemia

High blood sugars in a perioperative period in either group of diabetics or non-diabetics are linked to the increase in the morbidity and mortality postoperatively and therefore are considered an independent risk factor [48-49]. They are associated with the delay in wound healing and postoperative infections [48]. The patient’s outlook is improved if hyperglycemia in the perioperative period is well managed [48].

Blood Glucose Targets

Blood sugars above 180 mg/dl are found to be associated with morbidity, especially infections, and mortality [48]. At the same time, there is always a risk of hypoglycemia while attempting control of blood glucose [48]. This risk should be balanced with the cautious approach and the chances of this happening are decreased when blood sugars are targeted to keep in the range from 140-180 mg/dl. However, a wide range between 90-180 mg/dl of blood sugars is relatively easy to target [48].

Recommendations for the Perioperative Management of Blood Glucose

1. Fasting for a longer period should be avoided [48].

2. An attempt should be made to schedule surgery in the morning [48].

3. Blood glucose should be targeted < 180 mg/dl [48].

The approach to perioperative management of diabetes is depicted in Figure 1.
FIGURE 1: Approach to the Perioperative Management of Diabetes

HbA1c: Hemoglobin A1c; DPP4 Inhibitors: Dipeptidyl Peptidase 4 Inhibitors; GLP1 Agonists: Glucagon – Like Peptide 1 Agonists; SGLT2 Inhibitors: Sodium - Glucose Transporter 2 inhibitors

Limitations

In this article, the literature was reviewed pertaining to the perioperative management of blood sugars in patients with adult type 2 diabetes who undergo or being planned for surgery. No quality assessment tool has been applied and the articles over the last five years related to humans were selected. The research papers that were in the English language only were chosen and the studies in other languages were not made part of this article. Another limitation was to select those research articles only who were available as a free text on the database of PubMed. The articles with paid subscriptions were not studied.

Table 4 shows the list of articles that were relevant to the review article.
TABLE 4: Relevant articles

| SN | Author’s Name | Year of Publication | Country of Origin of the Study | Title of the Article | Important Points of the Study |
|----|---------------|---------------------|-------------------------------|----------------------|-----------------------------|
| 1  | Deniz Kuzulugil et al [1] | 2019 | Australia | Recent advances in diabetes treatments and their perioperative implications | Preoperative diabetes management is different from center to center. The convergent approach is required in patients with comorbidities. Sodium glucose transporter 2 inhibitors and sulfonylureas should be withheld before major procedures. |
| 2  | Gaëlle Cheisson et al [5] | 2018 | France | Perioperative management of adult diabetic patients | Diabetic control should be evaluated by using haemoglobin A1c and Blood glucose levels. Assess for gastroparesis, cardiac and renal status. Management should be individualized depending upon the comorbidities and type of surgery. |
| 3  | Gaëlle Cheisson et al [5] | 2018 | France | Perioperative management of adult diabetic patients | High blood sugars > 180 mg/dl peri-operatively carries the risk of morbidity and mortality. Hypoglycemia may occur when strict blood sugars control is attempted. |
| 4  | Gaëlle Cheisson et al [5] | 2018 | France | Perioperative management of adult diabetic patients | Meticulous monitoring of blood sugars is required to detect and manage hypo and hyperglycemia. Insulin infusion can be replaced with basal – bolus regime. Postoperatively, anti – diabetic medications are prescribed by taking into account previous use of medications, diabetic control, and comorbidities. |

Conclusions

Perioperative management of hyperglycemia is vital to avoid complications and successful outcomes. Blood sugars should be kept from 140 to 180 mg/dl, which is achieved through anti-diabetic medications. The choice of anti-diabetic medications depends on the number of factors including type and duration of surgery, comorbidities of the patients, and estimation of an early resumption of oral intake post surgery. In the usual practice, insulin is used to achieve target blood sugars in a perioperative state affecting the cost and requiring strict monitoring of labs. With the advent of new anti-diabetic medications, does the outlook remain the same or providing other options too? In the daycare settings, or when the patient is expected to be discharged soon, most of the anti-diabetics other than sulfonylureas and SGLT 2 inhibitors, can be continued perioperatively, thus, providing a wide range of choices. The sulfonylureas are associated with a risk of hypoglycemia whereas the SGLT 2 inhibitors are linked to causing diabetic ketoacidosis, especially euglycaemic ketoacidosis can be a tricky one to diagnose. The beliefs and fears surrounding metformin are overestimated and it can be used by assessing the overall situation. This emphasizes the individualized approach. The insight into the proper utilization of antihyperglycemic medications other than insulin can boost the confidence and comfort level of both clinicians and patients. However, although there is almost a consensus of keeping blood sugar between 140 and 180 mg/dl perioperatively, there is no universal guideline for the use of anti-diabetic medications in a perioperative state. In the future, this area might require further exploration to come up with more robust and uniform recommendations.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Kuzulugil D, Papeix G, Luu J, Kerridge RK: Recent advances in diabetes treatments and their
perioperative implications. Curr Opin Anaesthesiol. 2019 Jun 1; 32:398-404. 10.1097/ACO.0000000000000735
2. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al.: IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017, 128:40-50. 10.1016/j.diabres.2017.05.024
3. ([Accessed 13 January 2019]). Management of adults with diabetes undergoing surgery and elective procedures: improving standards [Internet]. Joint British Diabetes Societies for Inpatient Care. https://abdc.care/sites/abdc.care/files/resources/Surgical_guidelines_2015_full_FINAL_amended_Mar_2016.4
4. Dhatariya K, Levy N, Kilvert A, et al.: NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabet Med. 2012, 29:420-35. https://doi.org/10.1111/j.1464-5491.2012.05382.x
5. Cheisson G, Jacqueminet S, Cosson E, et al.: Perioperative management of adult diabetic patients. Preoperative period. Anaesth Crit Care Pain Med. 2018, 57:9-19. 10.1016/j.accpm.2018.02.020
6. Sato H, Carvalho G, Sato T, Lattermann R, Matsukawa T, Schricker T: The association of preoperative glycemic control, intraoperative insulin sensitivity, and outcomes after cardiac surgery. J Clin Endocrinol Metab. 2010, 95:4338-44. 10.1210/jc.2010-0135
7. Sathy B, Davis R, Taveira T, Whitlatch H, Wu WC: Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2013, 102:8-15. 10.1016/j.diabres.2013.05.003
8. Zhang X, Li T, Li Y, et al.: Protective effect of intraoperative re-dose of prophylactic antibiotics on surgical site infection in diabetic patients: a retrospective cohort study. Ann Transl Med. 2019, 10.21037/atm.2019.01.35
9. Martin ET, Kaye KS, Knott C, et al.: Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2016, 37:88-99. 10.1017/ice.2015.249
10. Satake K, Kanemura T, Matsumoto A, Yamaguchi H, Ishikawa Y: Predisposing factors for surgical site infection of spinal instrumentation surgery for diabetes patients. Eur Spine J. 2013, 22:1854-8. 10.1007/s00586-013-2783-8
11. Hemmerling TM, Schmid MC, Schmidt J, Kern S, Jacobi KE: Comparison of a continuous glucose-insulin-potassium infusion versus intermittent bolus application of insulin on perioperative glucose control and hormone status in insulin-treated type 2 diabetics. J Clin Anesth. 2001, 13:293-300. 10.1016/s0952-8180(01)00027-6
12. Ljungqvist O, Nygren J, Soop M, Thorell A: Metabolic perioperative management: novel concepts. Curr Opin Crit Care. 2005, 11:295-9. 10.1097/01.ccc.0000166395.65764.71
13. Thomas DJ, Platt HS, Alberti KG: Insulin-dependent diabetes during the peri-operative period An assessment of continuous glucose-insulin-potassium infusion, and traditional treatment. Anaesthesia. 1984, 39:629-37. 10.1111/j.1365-2044.1984.tb06469.x
14. McCall AL: Insulin therapy and hypoglycemia. Endocrinol Metab Clin North Am. 2012, 1:57-87. 10.1016/j.ecl.2012.05.001
15. Polderman JA, Van Steen SC, Thiel B, et al.: Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimen: a randomised controlled trial. Anaesthesia. 2018, 73:332-9. 10.1111/anae.14180
16. American Diabetes Association: Standards of medical care in diabetes—2019 abridged for primary care providers. Clin Diabetes. 2019, 37:11-34. 10.2337/cd18-0105
17. Ljungqvist O, Scott M, Fearon KC: Enhanced recovery after surgery: a review. JAMA Surg. 2017 Mar 1, 152:292-8. 10.1001/jamasurg.2016.4952
18. Barker P, Creasey PE, Dhatariya K, et al.: Peri-operative management of the surgical patient with diabetes 2015: Association of Anaesthetists of Great Britain and Ireland. Anaesthesia. 2015, 70:1427-40. 10.1111/anae.13253
19. Cosson E, Catargi B, Cheisson G, et al.: Practical management of diabetes patients before, during and after surgery: a joint French diabetology and anaesthésiology position statement. Diabetes Metab. 2018, 44:200-16. 10.1016/j.diabet.2018.01.014
20. ([Accessed 15 March 2019]). National Confidential Enquiry into Patient Outcome and Death, 'Highs and Lows,' [Internet]. London, 2018. Available from https://www.ncepod.org.uk/2018pd/Highs%20and%20Lows_Summary%20Report.pdf. The latest installment from the National Confidential Enquiry into Patient Outcome and Death team, with a retrospective case note and questionnaire review, examining the quality of care processes in adult diabetic patients in the perioperative period (being from time of primary care referral to discharge) provides useful insights into the many ways in which we deviate from ‘good practice,’ with recommendations for change. https://www.ncepod.org.uk/2018pd/Highs%20and%20Lows_Summary%20Report.pdf.
21. Lazarus B, Wu A, Shin JI, et al.: Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. JAMA Intern Med. 2018, 1:903-10. 10.1001/jamainternmed.2018.0292
perioperative glucose in patients undergoing coronary artery bypass grafting: a prospective randomized trial. Anesth Analg. 2018, 127:54-6. 10.1215/ANE.000000000003675

24. Ishikawa T, Koshizaka M, Maezawa Y, Takemoto M, Tokuyama Y, Saito T, Yokote K: Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus. J Diabetes Investig. 2018, 9:69-74. 10.1111/di.12676

25. Azoulay L, Suissa S: Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care. 2017 May 1, 40:706-14. 10.2337/dc16-1943

26. Zinman B, Wanner C, Lachin JM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 26:2117-28. 10.1056/NEJMlc1600827

27. Wiviott SD, Raz I, Bonaca MP, et al.: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 24:547-57. 10.1056/NEJMoa1902857

28. Neal B, Perkovic V, Mahaffey KW, et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 17:644-57. 10.1056/NEJMoa1611925

29. Abdul-Ghani MA, Norton L, DeFronzo RA: Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endor Rev. 2011, 23:515-31. 10.1001/er.2010-0029

30. Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X: Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017, 6:2824.

31. Blau JE, Tellah SH, Taylor SI, Rother KI: KETOACIDOsis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017, 33:2924. 10.1002/dmrr.2924

32. Goldenberg RM, Berard LD, Gilbert JD, Verma S, Woo VC, Yale JF: SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-64. 10.1016/j.clinthera.2016.11.002

33. Meyer EJ, Gabb G, Jesudason D: SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care. 2018 Apr, 1:47-9. 10.2337/dc17-1721

34. Kerridge R, Whyte I, Prior F, Lui J, Story DA: The good, the bad, and the ugly: sodium-glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes. 10.1171/030100571804600202

35. Peacock SC, Lovshin JA: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting. Can J Anaesth. 2018, 65:145-7. 10.1002/cja.21919

36. Garber AJ: Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011, 34:279-84. 10.2337/dc11-s231

37. Polderman JA, Van Steen SC, Thiel B, et al.: Perioperative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial. Anaesthesia. 2018, 73:332-9. 10.1111/anae.14180

38. Abuannadi M, Kosiborod M, Riggs L, House J, Hambarg M, Kennedy K, Marso K: Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endor Pract. 2012 Nov, 27:81-90. 10.1056/EP121196.0R

39. Pfeffer MA, Claggett B, Diaz R, et al.: The good, the bad, and the ugly: sodium-glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes. 10.1171/030100571804600202

40. Marso SP, Bain SC, Consoli A, et al.: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 28:311-22. 10.1056/NEJMoa1605827

41. Marso SP, Bain SC, Consoli A, et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 10:1834-44. 10.1056/NEJMoa1607141

42. Lips M, Mráz M, Kloučková J, et al.: Effect of continuous exenatide infusion on cardiac function and perioperative glucose control in patients undergoing cardiac surgery: a single-blind, randomized controlled trial. Diabetes Obes Metab. 2017, 19:1818-22.

43. Umpeierre GE, Smiley D, Jacobs S, et al.: Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011, 34:2654-61. 10.2337/dc10-1407

44. Lazar HL, Chpinik SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS: Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004, 30:1497-502. 10.1056/NEJMoa1509225

45. Blau JE, Tellah SH, Taylor SI, Rother KI: KETOACIDOsis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017, 33:2924. 10.1002/dmrr.2924

46. Goldenberg RM, Berard LD, Gilbert JD, Verma S, Woo VC, Yale JF: SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-64. 10.1016/j.clinthera.2016.11.002

47. Meyer EJ, Gabb G, Jesudason D: SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care. 2018 Apr, 1:47-9. 10.2337/dc17-1721

48. Kerridge R, Whyte I, Prior F, Lui J, Story DA: The good, the bad, and the ugly: sodium-glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes. 10.1171/030100571804600202

49. Peacock SC, Lovshin JA: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting. Can J Anaesth. 2018, 65:145-7. 10.1002/cja.21919

50. Garber AJ: Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011, 34:279-84. 10.2337/dc11-s231
controlled trial. J Thorac Cardiovasc Surg. 2012, 143:318-25. 10.1016/j.jtcvs.2011.10.070
47. Kempler P, Amarenco G, Freeman R, et al.: Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes Metab Res Rev. 2011, 27:665-77. 10.1002/dmrr.1223
48. Cheisson G, Jacqueminet S, Cosson E, et al.: Perioperative management of adult diabetic patients. Intraoperative period. Anaesth Crit Care Pain Med. 2018, 37:21-5. 10.1016/j.accpm.2018.02.018
49. Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger MA: Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005, 130:1144-1. 10.1016/j.jtcvs.2005.05.049